Recordati Rare Drug Patent Portfolio

Recordati Rare owns 4 orange book drugs protected by 15 US patents Given below is the list of Recordati Rare's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10709691 Pharmaceutical dosage forms 12 Oct, 2035
Active
US10143680 Pharmaceutical dosage forms 06 Jul, 2035
Active
US8415337 Ibuprofen compositions and methods of making same 02 Mar, 2032
Active
US8609862 Use of an adrenal hormone-modifying agent 13 Jan, 2031
Active
US9434754 Use of an adrenal hormone-modifying agent 13 Jan, 2031
Active
US8314097 Organic compounds 27 Mar, 2029
Active
US9351923 Extended-release composition comprising a somatostatin derivative in microparticles 23 May, 2028
Active
US7473761 Somatostatin analogues 14 Dec, 2026
Active
US7759308 Microparticles comprising somatostatin analogues 25 Oct, 2026
Active
US8835646 Organic compounds 23 Aug, 2026
Active
US8299209 Pharmaceutical composition comprising cyclic somatostatin analogues 27 Dec, 2025
Active
US8822637 Somatostatin analogues 06 Aug, 2023 Expired
US6344479 Method of preventing retinopathy of prematurity in a neonate 20 Mar, 2021 Expired
US6342530 Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt 14 Nov, 2020 Expired
US6225284 Somatostatin peptides 28 Jun, 2016 Expired


Given below is the list of recent legal activities going on the following drug patents of Recordati Rare.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 20 May, 2024 US8314097
Payment of Maintenance Fee, 12th Year, Large Entity 30 Apr, 2024 US8299209
Email Notification 13 Mar, 2024 US9434754
Recordation of Patent eCertificate of Correction 12 Mar, 2024 US9434754
Patent eCofC Notification 12 Mar, 2024 US9434754
Mail Patent eCofC Notification 12 Mar, 2024 US9434754
Payment of Maintenance Fee, 8th Year, Large Entity 06 Mar, 2024 US9434754
Court Processing Terminated 01 Mar, 2024 US7473761
Court Processing Terminated 01 Mar, 2024 US7473761
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US8314097
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US8609862
transaction for FDA Determination of Regulatory Review Period 23 Feb, 2024 US8609862
transaction for FDA Determination of Regulatory Review Period 23 Feb, 2024 US8314097
Post Issue Communication - Certificate of Correction 22 Feb, 2024 US9434754
Payment of Maintenance Fee, 4th Year, Large Entity 15 Jan, 2024 US10709691


Recordati Rare's Family Patents

Recordati Rare drugs have patent protection in a total of 62 countries. It's US patent count contributes only to 10.5% of its total global patent coverage. 12 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Recordati Rare Drug List

Given below is the complete list of Recordati Rare's drugs and the patents protecting them.


1. Isturisa

Isturisa is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10709691 Pharmaceutical dosage forms 12 Oct, 2035
(11 years from now)
Active
US10143680 Pharmaceutical dosage forms 06 Jul, 2035
(10 years from now)
Active
US8609862 Use of an adrenal hormone-modifying agent 13 Jan, 2031
(6 years from now)
Active
US9434754 Use of an adrenal hormone-modifying agent 13 Jan, 2031
(6 years from now)
Active
US8314097 Organic compounds 27 Mar, 2029
(4 years from now)
Active
US8835646 Organic compounds 23 Aug, 2026
(1 year, 10 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Isturisa's drug page


2. Neoprofen

Neoprofen is protected by 3 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8415337 Ibuprofen compositions and methods of making same 02 Mar, 2032
(7 years from now)
Active
US6344479 Method of preventing retinopathy of prematurity in a neonate 20 Mar, 2021
(3 years ago)
Expired
US6342530 Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt 14 Nov, 2020
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Neoprofen's drug page


3. Signifor

Signifor is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7473761 Somatostatin analogues 14 Dec, 2026
(2 years from now)
Active
US8299209 Pharmaceutical composition comprising cyclic somatostatin analogues 27 Dec, 2025
(1 year, 2 months from now)
Active
US6225284 Somatostatin peptides 28 Jun, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Signifor's drug page


4. Signifor Lar Kit

Signifor Lar Kit is protected by 5 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9351923 Extended-release composition comprising a somatostatin derivative in microparticles 23 May, 2028
(3 years from now)
Active
US7473761 Somatostatin analogues 14 Dec, 2026
(2 years from now)
Active
US7759308 Microparticles comprising somatostatin analogues 25 Oct, 2026
(2 years from now)
Active
US8822637 Somatostatin analogues 06 Aug, 2023
(1 year, 2 months ago)
Expired
US6225284 Somatostatin peptides 28 Jun, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Signifor Lar Kit's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List